The use of chemotherapy for localized large cell lymphoma. Results from the University of Arizona

  • S. E. Jones
  • T. P. Miller
Part of the Developments in Oncology book series (DION, volume 32)


Historically radiotherapy (XRT) alone has been used to treat non-Hodgkin’s lymphoma (NHL) of limited extent [1]. The rationale for this approach has included the ability to eradicate tumor in a treatment field and the apparent success of this approach in limited stage Hodgkin’s disease (HD). However, it has become clear that the NHL are a diverse group of lymphoid neoplasms clearly distinguishable from HD. The prototype curable NHL is the large cell or ‘histiocytic’ lymphoma. This differs from HD in that it occurs in older patients, has a high growth fraction with a propensity for rapid hematogenous dissemination, and fails to exhibit the classic radiation dose-response curve [2]. Thus, it is not surprising that many, if not the majority of patients with large cell lymphoma, fail to be cured with radiotherapy alone [1].


Complete Remission Malignant Lymphoma Initial Chemotherapy Southwest Oncology Group Study Historically Radiotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miller TP and Jones SE (1980). Is there a role for radiotherapy in localized diffuse lymphomas? Cancer Chemother Pharmacol 4: 67–70.PubMedCrossRefGoogle Scholar
  2. 2.
    Fuks Z and Kaplan HS (1973). Recurrence rates following therapy of nodular and diffuse malignant lymphomas. Radiology 108: 675–684.PubMedGoogle Scholar
  3. 3.
    DeVita VT, Canellos GP, Chabner BA et al. (1975). Advanced diffuse histiocytic lymphoma, a potentially curable disease: Results with combination chemotherapy. Lancet 1: 248–250.PubMedCrossRefGoogle Scholar
  4. 4.
    McKelvey EM, Gottlieb JA, Wilson HE et al. (1976). Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1484–1493.PubMedCrossRefGoogle Scholar
  5. 5.
    Jones SE, Grozea PN, Metz EN et al. (1979). Superiority of adriamycin containing combination chemotherapy in the treatment of diffuse lymphoma: A Southwest Oncology Group study. Cancer 43: 417–425.PubMedCrossRefGoogle Scholar
  6. 6.
    Miller TP and Jones SE (1979). Chemotherapy of localized histiocytic lymphoma. Lancet 1: 358–360.PubMedCrossRefGoogle Scholar
  7. 7.
    Cabanillas F, Bodey GP and Freireich EJ (1980). Management with chemotherapy only of Stage I and II malignant lymphoma of aggressive histologic types. Cancer 46: 2356–2359.PubMedCrossRefGoogle Scholar
  8. 8.
    Miller TP and Jones SE (1983). Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 62: 413–418.PubMedGoogle Scholar
  9. 9.
    Bonadonna G, Bajetta E, Lattuada A et al. (1984). CVP vs BACOP chemotherapy sequentially combined with irradiation in Stage I-II diffuse non-Hodgkin’s lymphomas. In: Jones SE and Salmon SE (Eds.). Adjuvant Therapy of Cancer. IV. New York: Grune and Stratton. In press.Google Scholar
  10. 10.
    Skarin AT, Canellos GP, Rosenthal DS et al. (1983). Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents ( M-BACOD ). J Clin Oncol 1: 91–98.PubMedGoogle Scholar
  11. 11.
    Skarin A, Cannellos G, Rosenthal D et al. (1983). Moderate dose methotrexate (m) combined with bleomycin (B), adriamycin (A), cyclophosphamide (C), oncovin (o) and dexamethasone (D), (m-BACOD), in advanced diffuse histiocytic lymphoma ( DHL ). Proc Amer Soc Clin Oncol 2: 220.Google Scholar
  12. 12.
    Fisher RI, DeVita VT, Hubbard SM et al. (1983). Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98: 304–309.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • S. E. Jones
    • 1
  • T. P. Miller
    • 1
  1. 1.Section of Hematology and Medical Oncology, Department of Medicine and Cancer CenterUniversity of Arizona Health Sciences CenterTucsonUSA

Personalised recommendations